Targets › DNAG
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 3; Immunology, Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on DNAG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nishtar Medical University | nadifloxacin Fluoroquinolone antibiotic with broad-spectrum activity against acne-causing bacteria | DNAG, DNAB | Phase 4 | Acne Vulgaris | Mar 2027 |
| Tanta University | Gemifloxacin Fluoroquinolone; topoisomerase II (DNA gyrase) and topoisomerase IV inhibitor | DNAG, DNAB | Phase 3 | Spontaneous Bacterial Peritonitis | Dec 2028 |
Acne Vulgaris (1) Spontaneous Bacterial Peritonitis (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.